BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12901485)

  • 1. Case report: Molluscum contagiosum. Toxic shock syndrome following cantharidin treatment.
    Langley JM; Soder CM; Schlievert PM; Murray S
    Can Fam Physician; 2003 Jul; 49():887-9. PubMed ID: 12901485
    [No Abstract]   [Full Text] [Related]  

  • 2. Cantharidin therapy for molluscum contagiosum in children.
    Epstein E
    J Am Acad Dermatol; 2001 Oct; 45(4):638. PubMed ID: 11568766
    [No Abstract]   [Full Text] [Related]  

  • 3. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    Eichenfield LF; Siegfried E; Kwong P; McBride M; Rieger J; Glover D; Willson C; Davidson M; Burnett P; Olivadoti M
    Am J Clin Dermatol; 2021 Mar; 22(2):257-265. PubMed ID: 33599960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
    Niazi S; Brabec B; Anschutz L; Willson C; Davidson M; Burnett P
    J Drugs Dermatol; 2021 Jan; 20(1):70-75. PubMed ID: 33400412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beetle juice: a guide for the use of cantharidin in the treatment of molluscum contagiosum.
    Moye V; Cathcart S; Burkhart CN; Morrell DS
    Dermatol Ther; 2013; 26(6):445-51. PubMed ID: 24552407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients.
    Silverberg NB; Sidbury R; Mancini AJ
    J Am Acad Dermatol; 2000 Sep; 43(3):503-7. PubMed ID: 10954663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of molluscum contagiosum with cantharidin: a practical approach.
    Mathes EF; Frieden IJ
    Pediatr Ann; 2010 Mar; 39(3):124-8, 130. PubMed ID: 20302243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cantharidin Topical Solution 0.7%: First Approval.
    Keam SJ
    Paediatr Drugs; 2024 Jan; 26(1):95-100. PubMed ID: 38007409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum.
    Khattab FM; Nasr MM
    J Dermatolog Treat; 2020 Dec; 31(8):850-854. PubMed ID: 31418621
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients.
    Ross GL; Orchard DC
    Australas J Dermatol; 2004 May; 45(2):100-2. PubMed ID: 15068455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection.
    Cathcart S; Coloe J; Morrell DS
    Clin Pediatr (Phila); 2009 Mar; 48(2):161-5. PubMed ID: 18936288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
    Vakharia PP; Chopra R; Silverberg NB; Silverberg JI
    Am J Clin Dermatol; 2018 Dec; 19(6):791-803. PubMed ID: 30097988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molluscum Contagiosum: An Update.
    Leung AKC; Barankin B; Hon KLE
    Recent Pat Inflamm Allergy Drug Discov; 2017; 11(1):22-31. PubMed ID: 28521677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe and speedy cantharidin application.
    Lao M; Weissler A; Siegfried E
    J Am Acad Dermatol; 2013 Aug; 69(2):e47. PubMed ID: 23866889
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial.
    Guzman AK; Schairer DO; Garelik JL; Cohen SR
    Int J Dermatol; 2018 Aug; 57(8):1001-1006. PubMed ID: 29904968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertically transmitted molluscum contagiosum infection.
    Luke JD; Silverberg NB
    Pediatrics; 2010 Feb; 125(2):e423-5. PubMed ID: 20064865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cantharidin: a comprehensive review of the clinical literature.
    Torbeck R; Pan M; DeMoll E; Levitt J
    Dermatol Online J; 2014 Jun; 20(6):. PubMed ID: 24945640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum.
    Coloe J; Morrell DS
    Pediatr Dermatol; 2009; 26(4):405-8. PubMed ID: 19689514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    Eichenfield LF; McFalda W; Brabec B; Siegfried E; Kwong P; McBride M; Rieger J; Willson C; Davidson M; Burnett P
    JAMA Dermatol; 2020 Dec; 156(12):1315-1323. PubMed ID: 32965495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cantharidin in Dermatology.
    Al-Dawsari NA; Masterpol KS
    Skinmed; 2016; 14(2):111-4. PubMed ID: 27319954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.